Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks pennypauly. Nice close today +8.6% on a rugged market day.
My entry from just before the close yesterday looks a good choice.
$AMBS has an interesting background. I read back some posts and appreciate the effort several of you have put in to help me get up to speed.
I am a technical guy. The AMBS chart really stood out, and the fundamentals confirmed my decision.
Thanks, It is confusing right?
I just know something is here. (wishful thinking at this time)
I guess one problem with me is when I look at what I sold to add to ABMC which is major red like $40k and the other good companies are up like like 50-200%.
I still feel we will be OK though.
Applause !!!
I do not DM with anyone often. But last week I did contact them.
I can tell you that their frustration, and a deep anger, just came shooting out of my monitor like flames from hades.
And if you do not believe me, read back and find a single post I ever tried to manipulate this board. I post facts and if it is an opinion, it is clearly just an opinion.
I trust them more than I do this management, in the sense that I know they worked 100% to get share price up. Now I said it!
$.06 to $1.26 on them alone! I physically could not do what they did. I have thanks for @AdamS007 and @SPORTYNORTY and everyone that put in a ton of hours to make that run.
And it was not a pump and dump. It was a run up on real potential and dump by management.
Our previous cheerleaders did not sell, anything, so they may be back if things change.
I'll be the first to invite them. Lot's of interesting info came out on the first run.
Information wise, I got nothin new.
Only NASDAQ by accounting standards. And that is the only reason I am still here.
If this were any other OTC, I would have taken profits and gone to sing with July Andrews in the Alps.
Can I join you guys over here?
I like what I see and want to make new friends.
Well, as you read in a previous post, when I was not in such a cheerful mode, I am in the same position as you and several others.
The only thing I did right is that I did not add to my position after .60's on the way up and I did not buy anything on the way down at all. Still, I am major in the red like everyone else.
This is the ONLY stock I have held my entire position after a big run in many many years. I am quite disciplined. SAVE YOUR PRINCIPLE! In reality I guess I am not disciplined, am I?
Like you, I felt there was something more here, and I still do.
Price support levels were clear, and it tried to hold at several of these points. So that was a good try. But with continually decreasing volume as I was charting, support just had no chance.
We just did not get any help. And this is such a unique problem to have. Confusing actually. Very confounding.
Now, at these prices I am considering buy orders. So lets just consider that we are starting fresh, but with more experience. Consider that our total orders are filled and we are ready for what "should happen" (can't say "know" any longer) and we are ready to move up again, on fundamentals only.
And, if we do not get a single PR, be sure millions of shares will be selling into any run the company actually starts to initiate. Not sure they will be happy at that time.
I see the reversals also. Support is just holding in a major losing market day.
ABMC is now fighting other market factors. Let's see what tomorrow holds for us.
$PURE reports record revenues, Repost from June 6,
and profits. Highlights below!
Revenues for the fiscal third quarter in 2020 increased 612%
Net income per share was $0.01 for the fiscal third quarter in 2020, compared to a net loss of ($0.03) for the fiscal third quarter in 2019.
Gross margin was 56% for the three months ended April 30, 2020
Revenues for the nine months ended April 30, 2020 increased 129%
$PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2020 and the nine-month period ended the same date.
Highlights:
Tom Y. Lee, Chief Executive Officer summary
“With the achievement of profitability, I’m pleased to note that revenue for our fiscal fourth quarter is expected to meet or exceed our fiscal third quarter revenue.”
“Due to increased and continued demand, we have expanded our production capacity. Our primary contract manufacturer has invested significant amounts to improve lead-times and volume, allowing us to manufacture bulk product in two Midwest locations with further expansion underway."
“For the first time in the company’s history, PURE is profitable. During the third quarter, sales to our distribution network significantly increased due, in part, to our recently announced partnership with Packers Sanitation Services, Inc. (PSSI) and our alliances with Whiting Systems, Inc. and Marathon Group, LLC. We look forward to expanding our relationships with PSSI, Whiting and Marathon, all respective leaders in their industries with national and global reach."
PURE® Hard Surface
-Food Processing and Manufacturing: PURE Hard Surface is now available for use in over a thousand protein, produce, bakery, and dairy facilities across the United States
-Transportation Sanitization: PURE’s Transport Sanitation Solution, designed to meet the FDA Food Safety Modernization Act (FSMA) requirements, is now being used by three of the nation’s largest food transportation companies servicing restaurant chains, food processors and grocery store chains
-PURE’s Transport Sanitation Solution across multiple channels, including prisons/jails, hospitality, education and more
PURE Control®
SmartWash® Boost: delays and economic impacts related to COVID-19 have impacted final third-party validation of SmartWash® Boost. Nonetheless, SmartWash remains committed to bringing the revolutionary Boost product to market to treat pre-cut lettuce as a further intervention step to protect America’s food chain. A senior executive of Taylor Farms was recently quoted saying, “Clearly, there is a path forward for Boost to play an integral part in ensuring the safety of the United States produce supply.”
While five facilities are operating using PURE Control, the planned rollout at a multinational produce processor was slowed by the events of the first calendar quarter of 2020. All plans remain in place and are expected to move forward to additional locations for berry and tomato processing. The same multinational corporation adopted PURE’s Environmental Solution for all 21 of its locations, including corporate offices for facility and employee safety.
To date, work is ongoing with multiple additional processors for treatment of herbs, tomatoes, onions, broccoli, cabbage, berries, processed grapes, leafy greens and cut lettuce.
https://www.marketwatch.com/press-release/10-q-pure-bioscience-inc-2020-06-11?mod=mw_quote_news
https://last10k.com/sec-filings/pure/0001493152-20-011000.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=pure
https://m2compliance.com/hosting/company/PURE/link_files/2020/06-11-2020/Form10-Q(06-11-2020)PureBioscience/Form10-Q.pdf
I can't disagree with you at all.
Every one of your points is valid, yet here we are.
A great company, that has an opportunity to do well. Should I use the word- squandering a great opportunity as you insinuate.
Maybe, they have a plan to get to $5.00 and NASDAQ again. We have no clue that is even their motivation. That would be exciting!
It does make me wonder why they stay GAAP accounting, spending tens of thousand annually on auditors, etc. Just to be hovering at $.06 share price before Corona virus hit.
I am down a good amount of dollars here, but most of the hurt is the paper loss. We will make this up again and lesson learned, right?
Agreement with your rant over
ABMC is still the best OTC and NASDAQ investment in this niche and is why I am here. It is possibly the largest percent gainer available from any ticker at this time.
The larger NASDAQ companies are showing great earnings right now, but percentage gains will not be as great as we have here. ABMC has already proven potential by the +1000% we had in June/July.
The vast majority of the OTC/PINK's in this niche are scam companies. Trading on hype. One or two have an opportunity to trade with ABMC. They have good test products, but they are still cleaning up their corporate structure.
For ABMC:
The earnings will be here.
The management is honest.
It is just excruciatingly slow.
They do not realize that many "traders" would be "investors" if there was more corporate support. The float was sucked up in July, now shares are released back into the market. Just lost opportunities for them and us. But, I am confident it will return or I would have moved on.
I speak clearly that my position would easily be double if we held support, say in the $.70's where so many of us were adding and many others would have done the same.
They just don't care Patientlyimpatient. I'll rant and hope I am wrong-
I see your point, but this management and this board have hardly made any material changes in like 10 years. That is why I am weary about trying to change the status quo. We have been trying to get communication and help for the past 6 months.
No new profitable product lines to supplement the older drug test kits. No marketing, no publicity because they do not want to advertise to competitors what is going on.
New product and clients just brought in end of 2019. The Healgen test was probably being negotiated from what, maybe February?
That burst of filings, that high energy in June of Form-4 was so that everyone that was eligible for cheap shares received them. Now back to the status quo.
They are intelligent people, keeping the company alive through the challenging times. So we wonder what is the next move up their sleeve? The reality is that there does not seem to be a next move.
So I go with fundamentals and luck that some promoter will try to run it because the float is thin.
In saying this, we can all hope this entire comment is wrong, and I would like it to be wrong.
Can someone on the team contact MP Biomedicals to get a better picture of their relationship?
https://www.mpbio.com/about-us
I have always been curious.
The close is still at the top end of the consolidation zone. So this is positive.
Volume was only 18% of average, continuing the trend. Not a positive.
Basically the chart remains unchanged.
The only solution I can see is correction by a large position owner of ABMC. I do not understand how this can continue.
Valiant Co Ltd owns 13% of $ABMC and is a 16.237 BILLION Market cap company
MP Biomedicals owns 13% or 4.7 mil shares of $ABMC
https://www.otcmarkets.com/filing/html?id=14287313&guid=5sFFUHVJ3H_cg3h
MP Biomedicals is a wholly-owned subsidiary of Valiant Co., Ltd.
https://www.mpbio.com/about-us
Valiant Co., Ltd. has 3,250 total employees across all of its locations and generates $413.44 million in sales (USD). There are 19 companies in the Valiant Co., Ltd. corporate family.
http://www.valiant-cn.com/about.aspx
Public listing:
https://sg.finance.yahoo.com/quote/002643.SZ/
It is definitely not time for MP Biomedicals to ignore the moves $ABMC has been making.
Important connection or...?
The board and management are as one. In a nice way, I am saying drop the idea of changing anything, it is getting old and it is unfortunate for investors.
We will see $2.00+ again.
Chart is interesting. In June I saw resistance from 2016-01-11 price levels at $1.49. It blew right past that to $1.61 then $1,91 and HOY $2.05. I was confused that share price did not even slow down at $1.49.
Now that we pulled back and retraced here is that $1.49 resistance.
Charting is pure fun.
Let's see if we begin to gain volume on this next run. We have to reuse the ammunition we had in May and June if no further PR's are released.
Subslover, a bit of history. This post was when we were at $1.38 and three days later hit $2,05.
Thanks for the update seeking wisdom
Your welcome Namtro. ABMC is feeling exciting again since it is consolidating nicely here and we do not have to be concerned on share price dropping much at these levels and good earnings expected.
I just took a look at what two of our previous cheerleaders for ABMC are doing @AdamS007 and @SPORTYNORTY and they are really making bank right now. They earned my thanks for helping me with ABMC for sure.
However, I am thinking I am spending waaayyy to much time around here.
Think I will just sit back and enjoy the next run up.
rain
A second Covid-19 test would be great.
I can see them doing PPE as an add on to the COVID-19 test kit sales. I would agree if they tried to do this as a stand alone product line it would be difficult.
Perhaps someone could email the question.
"other infectious disease products" from the first quarter 10-Q.
Can anyone elaborate so that I do not get off track?
We can expect elaboration on this next filing for this
10-Q from first quarter.
Comments in the order I pulled them from the filing.
There are numerous positive statements here.
Late in the First Quarter of 2020, we began marketing a Rapid Test to detect Covid-19 antibodies in whole blood, serum or plasma. The test, manufactured by Healgen Scientific, LLC is being marketed in full compliance with the March 16, 2020 Emergency Use Authorization (“EUA”) policy set forth by the FDA and in accordance with an EUA issued by FDA on May 29, 2020. Due to specific regulatory events that occurred from March 2020 until May 2020, we did not record any sales of Covid-19 tests, although we did take pre-orders (with payments) for Covid-19 tests.
In addition to the Covid-19 rapid antibody tests, we have brought on new products and service offerings to diversify our revenue stream through third party relationships; one of which is a lower-cost alternative for onsite drug testing and, point of care products for certain infectious diseases. With the exception of the lower-cost drug test alternative, (and Covid-19 rapid antibody tests sold subsequent to the First Quarter 2020), these new offering have yet to materially positively impact sales.
We are hopeful that gaining access to this market again will enable us to see revenue growth for our oral fluid drug tests in the future; however, we are uncertain when in the year ended December 31, 2020 we could start seeing significant sales in the employment market given the current global health crises and Covid-19
We are focusing our efforts on further penetration of markets with new products, including, but not limited to, the Covid-19 rapid antibody test we are distributing along with other infectious disease products we are offering, and further expanding our contract manufacturing business.
Our continued existence is dependent upon several factors, including our ability to: 1) raise revenue levels even though we have lost significant accounts and the market continues to be infiltrated by product manufactured outside of the United States, 2) further penetrate the markets (in and outside of the United States) for Covid-19 rapid antibody tests, 3) secure new contract manufacturing customers, 4) control operational costs to generate positive cash flows, 5) maintain our current credit facilities or refinance our current credit facilities if necessary, and 6) if needed, obtain working capital by selling additional shares of our common stock.
The First Quarter 2020 did not include any revenues from the sale of Covid-19 rapid antibody tests. Although we were able to generate prepaid, pre-sales of the Covid-19 tests late in the First Quarter 2020, we did not start shipping products and generate revenue until May 2020. Prior to May 2020, there were a number of regulatory events that resulted in an inability to get the supply of products from the manufacturing plant in China. Once those events were addressed, we were able to receive product and ship orders to customers. As of the date of this report, we have shipped $1,126,000 in products to customers and there are additional orders pending from customers. (End of May-July 31 = TWO MONTHS)
While we do expect the marketing of the Covid-19 test to further positively impact our revenues in the year ending December 31, 2020, we do not yet know the full extent of the impact of COVID-19 test sales on our business, our financial condition and/or results of operations. The extent to which sales of the COVID-19 test may impact our business, operating results, financial condition, or liquidity in the future will depend on future developments which are evolving and uncertain including the duration of the outbreak and the need for antibody testing in the future.
As of the date of this report, gross margins have improved as a result of Covid-19 rapid antibody test sales. At this time, it is uncertain whether the current profit margins of Covid-19 test sales will continue at the present rate. Various factors can affect marketing pricing (such as an increased number of EUA issued products and their availability to customers, and costs of materials to manufacture the Covid-19 tests. We are continually taking actions to adjust our production schedules to try to mitigate future inefficiencies and we closely examine our gross profit margins on our manufactured products and the products we distribute.
In late March 2020, we also started selling a Covid-19 rapid antibody test from Healgen Scientific, LLC via a distribution relationship. As of result of this new product offering, we do expect sales commission rates to increase as sales are achieved. We may also increase the size of our sales team depending on the level of sales achieved. We will continue to take all steps necessary to ensure selling and marketing expenditures are in line with sales.
We expect to devote capital resources related to selling and marketing initiatives. We are examining other growth opportunities including strategic alliances. Given our current and historical cash position, such activities would need to be funded from the issuance of additional equity or additional credit borrowings, subject to market and other conditions.
We are promoting new products and service offerings to diversify our revenue stream, including a Covid-19 rapid antibody test. We also secured the business of two (2) new contract manufacturing customers.
8-K Comments in the order I pulled them from the filing.
Waterhouse continued, “We started generating sales of the rapid antibody test in May 2020. Since our last press release update on June 26, 2020, we have continued to sell the rapid Covid-19 antibody tests. Although market demand for antibody testing can fluctuate as infection surges occur (due to the higher demand for diagnostic testing), we are still recording sales. These sales are for now offsetting our drug testing declines. We believe there is an opportunity for Covid-19-related sales to contribute significantly to our 2020 financial results.”
Let me know if I missed anything.
The Rainbow
Oh oh, the magic light! I ran away from that one and went to PURE for one of the best FDA approved sanitizers on the market. It was my best move on my way to ABMC which hopefully is my next best move.
Agreed, the right catalyst will move us upward.
$ABMC is a turn around company with a bright future, fully reporting which is unheard of in the OTC Marketplace.
We expect to get the second quarter 10-Q this week showing the first full month revenues for the Healgen Covid-19 test kit from June.
We should get great revenues through August 31.
The big question, will we see any:
Subsequent events
PR's
Forward Guidance
We know there is much info there, but will we see it?
Chart is looking incredible when combined with today's price action.
There has been pressure on the ask with a large spread.
I have to reevaluate how hard the price can move upwards if we get volume. In April/May we traded a much tighter range on slightly higher volume as compared to the past week.
If we can get volume to break the volume downtrend line, we can easily see gains of 20-30% daily until the MM catch on again.
I am open to comments
Well bk, I did not want to get technical but since you put it in my head, I'll have to clarify or I won't be able to sleep tonight. (In the future it may be best to ignore me )
At close today
ABMC is up 525% from year low close to present close on earnings.
DECN is up 1,397% for the same period by spamming and fake news. (And I would never touch.)
My point is that $ABMC will return to high of year and remain a sustainable company while DECN will drop back down to PINK sheet flames and burn, but PR is working for one and not for the other.
Even ABMC was having a difficult time before March which is when they came back to life for getting on top of COVID-19 opportunities quickly and with a great product.
Healgen rapid test distributed by $ABMC showed 100% sensitivity and 100% specificity ranking in the top 5 of 62 evaluated tests.
A recently published Canadian study reported that the Healgen rapid test distributed by $ABMC is still one of the top in the world.
Article Title: Not all COVID-19 antibody tests are created equal, but which ones are best?
https://www.studyfinds.org/not-all-covid-19-antibody-tests-are-created-
Other than DECN being up 400% on the year, I am not seeing what I posted that had any positive material on the scam company at all. Let me know and I'll correct it.
Have to admit the promoters are doing their job well. Sad they do better promoting a scam than a real company like $ABMC.
Agree with you that we all know $ABMC is one of the few companies in OTC land that has any potential to do well.
Nice close today up 10.53% at $.315
DECN releases a spam PR for new Saliva tests. International Version GenViro! Saliva Swift :10.5 Second Covid-19 Kits
Their first test was withdrawn from the market and it is doubtful the new test will work either.
Still DECN is up 400% on the year. Trading Caveat Emptor which is below the stop sign and they have no filings at all.
SEC announced an action against DECN, suspending trading in the company's stock for two weeks.
The question is- why is share price doing so well?
Yet $ABMC lags. The company will be releasing Q2 which should give us guidance on what to expect for Q3 which is expected by all of us to be very profitable.
Decision Diagnostics Corp. (OTC PINK:DECN) a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters today announced that we have set September 26, 2020 as the launch date for our International version GenViro! Covid-19 Saliva Swift Kit.
The company has notified its Korean manufacturing partner that it will place an initial order for 100,000 kits on that day. As of that same day DECN will accept orders from International distributors.
The first shipments are expected to be sent to India with an initial order for 50,000 kits. The company will wholesale the International GenViro! Swift Kits at an introductory price of $8.95 . The suggested retail price has yet to be determined and might vary by country.
"While we anticipate US FDA approval, we recognize that the rest of the world can use the benefits Genviro! provides," said Berman. "Our international distributors will be responsible for capturing any certifications or approvals required to produce sales and we look forward to working with distributors around the globe to quickly bring this accurate, affordable, simple and scalable testing solution to market."
The only OTC in my COVID-19 test kit company index making a profit is $ABMC.
Upwards price action is very real on strong earnings.
The other OTC's promoting tests are either waiting for FDA EUA approval, jumped in distributing lower quality tests, or are still waiting for sales.
I believe chart price resistance levels I predicted quite accurately from the initial run up in June remains. But, will be more difficult to overcome this time around unless the management has a plan to help with PR.
$ABMC has added several additional drug tests expected to add to revenues for 2020 as reported in the past two filings.
This report confirms the need for additional drug testing.
"The number of working Americans testing positive for drugs climbed last year, particularly for marijuana, according to a new report, indicating employee drug use was on the rise just as the coronavirus pandemic created new stresses.
Overall, the percentage of U.S. workers who tested positive for drugs in urine in 2019 rose to 4.5%, the highest level in 16 years, according to Quest Diagnostics Inc. , one of the largest drug-testing laboratories in the U.S., which analyzed approximately nine million tests last year on behalf of employers.
That percentage was 29% higher than the 30-year low of 3.5% a decade ago, in the early days of a resurgent heroin epidemic in the U.S.
In more recent years, more positive tests for methamphetamine and cocaine have helped to fuel the increase in the share of employees testing positive for drugs."
Florida Dept. Health
@HealthyFla
@GovRonDeSantis
is ordering all Florida executive agencies to sever their COVID-19 testing relationships with Quest effective immediately. Per Quest, all individuals that tested positive were notified of their results.
This will have Florida put more emphasis on Rapid Testing where $ABMC has a strong presence.
So announced on Twitter: Florida cutting Quest Diagnostics saying 75k results were delayed in being reported to state. Quest does not dispute the fact but does say positive results were returned to patients directly. This was 75k tests out of 14m.
Chart indicators, volume and sentiment is very strong for $PURE today. The past week has shown strong support.
Subway and Chipotle are listed as two of the largest "food establishments" that are using SDC. Add to them the new distributorship agreements valued in the millions of dollars.
Are you insinuating that sales are not adequate for this market niche or are you asking how strong $ABMC's market share actually is?
I can re post my previous comment:
Charge whatever the market will bear — honestly.
This is a quote I read recently and is how I have always based the value of my services to my clients.
ABMC's bottom line is based on the cost of distribution and overhead, etc., which we do not know, plus a markup for profit. Speculating or debating on what these costs are at this time, or the availability of the test is fruitless and wearisome. The Q, with some answers, will be filed any day now.
We will get more info on sales, product availability and perhaps even pricing in the filings for Q2.
Then we can extrapolate further investment decisions from there. Buy, sell, strengthen positions, can be decided after the next Q, which will provide some guidance at least for 2020.
I am not following your thoughts on AYTU that was also selling a second test that lost their FDA EUA and the Abbot test that will only be used by first responders and front line workers at this time.
Good synopsis bk1287.
Thanks bk. Was hoping you would post that.
Product availability is such a non issue. I do not know why it pops up. Whack a Mole I guess.
Be careful promoting this particular article too heavily because it is paid advertising. It is well written and I find the information generally useful. It does seem we will be hit by both the Corona virus and the Flu when the cool season hits. But, it is still paid adverting. Good luck.
Disclaimer
COMPENSATION: Bullishguru.com & Dailytrendingstocks.com charge weekly compensation starting from two thousand dollars per week, which goes towards ad placement and creation of company profile on our website
https://dailytrendingstocks.com/disclaimer/
ALST Sets Up as a Key “Twindemic” Play this Fall
28 Aug 2020, Friday
The new buzzword to watch this fall? Twindemic.
This is the theory catching wind in the media and in expert circles that we are headed for a feedback loop escalation of both Covid-19 and influenza, reinforcing each other, as we approach the coming cold and flu season.
https://dailytrendingstocks.com/alst-sets-up-as-a-key-twindemic-play-this-fall/